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Abstract
This study described the cerebrospinal fluid (CSF) exposure of vancomycin in 8 children 
prescribed intravenous vancomycin therapy for cerebral ventricular shunt infection. Vancomycin 
CSF concentrations ranged from 0.06 to 9.13 mg/L and the CSF: plasma ratio ranged from 0 to 
0.66. Two children out of three with a staphylococcal CSF infection had CSF concentrations > 
minimal inhibitory concentration at the end of the dosing interval.
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Cerebral ventricular shunt infections are a common cause of shunt failure and occur in 11% 
of children with shunts.1 In this setting, vancomycin is the most commonly used 
antimicrobial drug because staphylococcal species account for nearly 75% of shunt 
infections.2 Successful cerebrospinal fluid (CSF) sterilization depends on optimal drug 
exposure and, despite its widespread use, limited vancomycin CSF pharmacokinetic (PK) 
data are available in children. This study describes the CSF exposures of vancomycin in 
children with a shunt.
Methods
This was a prospective, single-center, open label PK study of intravenous (IV) vancomycin 
in children with suspected or documented ventricular shunt infection. Children <18 years of 
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age were included if they received IV vancomycin and had CSF collected per standard care. 
Vancomycin dosing, infusion rate and duration of treatment were prescribed at the discretion 
of the treating physician. This trial was approved by the institutional review board of the 
Duke University Medical Center.
CSF was collected as part of standard of care through ventricular or CSF reservoir tap, if the 
subject had a shunt, or by lumbar puncture if no shunt was present. Vancomycin serum 
concentrations and dosing were retrospectively recorded from routine therapeutic drug 
monitoring.
Serum PK samples were analyzed by immunoassay in the Duke Hospital Clinical 
Laboratory using a validated assay under Good Laboratory Practice (GLP) standards. CSF 
PK samples were analyzed using a validated liquid chromatography–tandem mass 
spectrometry assay (HPLC/MS/MS).
The serum PK of vancomycin was characterized using nonlinear regression in WinNonlin v.
6.3 (Pharsight Co., St. Louis, MO). A one-compartment model with zero-order infusion was 
used to fit the serum PK data based on previous vancomycin PK models in children.3 The 
model fit was evaluated using standard model goodness of fit criteria. Vancomycin CSF 
penetration was measured using the ratio of CSF to serum concentrations (CSF: serum) at 
the same time point. Because serum and CSF concentrations (Cserum and CCSF) were not 
sampled simultaneously, Cserum was predicted at each CSF sample time point using the 
following equation:
where Cmax is the predicted maximal serum concentration; ke the elimination constant in 
serum and t the time of CSF sampling. Using the same equation, serum trough concentration 
(Cmin) was also predicted during the dosing interval when CSF was sampled.
As a pharmacodynamics (PD) endpoint, CCSF was compared with minimum inhibitory 
concentration (MIC) of vancomycin for children with bacteriologically proven infection. 
MIC was determined by the clinical microbiology laboratory using validated broth 
microdilution method or Etest.
Demographics and clinical characteristics were summarized using descriptive statistics using 
STATA 12 (College Station, TX).
Results
Serum and CSF samples were obtained from 8 children (4 males) with a median (range) age 
of 4.3 years (0.2, 17), a weight of 14 kg (1, 116), and a serum creatinine of 0.42 mg/dL 
(0.13, 0.82) (Table 1). All children had a cerebral ventricular shunt except for one subject 
who had a history of external ventricular drain that was removed 7 days prior to the lumbar 
puncture. Among the 5 children (63%) who had a positive CSF culture, 2 had a methicillin-
resistant Staphylococus aureus (MRSA) (vancomycin MIC of 0.75 and 1 mg/L) and 1 had a 
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Staphylococcus epidermidis (vancomycin MIC of 2 mg/L). All children with confirmed 
infection underwent externalization of their ventriculo-peritoneal shunt and placement of an 
external ventricular drain. Shunt was internalized when CSF cultures were negative as 
decided by the treating physician. All children with confirmed infection were cured and did 
not have recurrent infection over a 6 month period. Of the 3 children with confirmed 
Staphylococus sp infection, subject #2 and #8 cleared the infection after 3 days of 
vancomycin therapy, whereas subject #5 had persistent MRSA in CSF on day 3 and had his 
first negative CSF culture on day 5. The median vancomycin dose was 19 mg/kg/dose (11, 
30) every 8 hours (7–13) for a mean duration of 17 days (4, 27). The median number of 
doses received prior to PK sampling was 47 (7–74).
Of the 8 children enrolled, one was excluded from the serum PK analysis because only a 
single serum sample was collected. The median number of serum and CSF samples per child 
was 5 (1, 14) and 2 (1, 3), respectively, resulting in a total of 43 and 12 serum and CSF 
samples, respectively. In serum, the median CL was 0.08 L/h/kg (0.05, 0.15), V was 0.70 
L/kg (0.22, 4.46) and ke was 0.12 /h (0.02, 0.26). The median predicted serum Cmin was 
11.5 mg/L (3.9, 32.1).
The median CCSF was 1.07 mg/L (0.06, 9.13), and CSF:serum ratio was 0.08 (0, 0.66). 
Visual inspection of scatter plots suggested no relationship between CSF:serum ratios and 
age, time after last dose, or CSF white blood cell count (data not shown). However, it 
appeared that CSF: serum ratio increased as CSF protein level increased (data not shown).
The 2 children with MRSA meningitis had CCSF (1.15 and 9.13 mg/L) above the 
vancomcyin MIC (0.75 and 1 mg/L) at the end of the dosing interval. The child with the S. 
epidermidis isolate had a CCSF (0.06 mg/L) below the MIC (2 mg/L) 5 h after the previous 
dose.
Discussion
Assessment of CSF vancomycin exposure of children with shunt infection is critical because 
this compartment represents the drug’s site of action. The range of CCSF (0.06, 9.13 mg/L) 
in our small cohort was similar to previous studies in children (0 to 6.6 mg/L).4–7 A wider 
range of concentrations has been reported in adults (0.1, 22.3 mg/L).8,9 This variability 
could be caused by a number of factors, including different vancomycin dosing and CSF 
sampling times, age-related changes in blood brain barrier (BBB) and blood-cerebrospinal 
fluid barrier permeability, and different disease states. Limited data suggest increased drug 
diffusion into CNS with decreasing age.10 However, no relationship between age and CSF 
penetration was observed in our small cohort. In addition to maturational change, variability 
could be explained by difference in disease state. Inflammation associated with meningitis is 
thought to increase drug BBB permeability, resulting in higher CSF concentrations.11 In the 
present study, the subject who had the highest CCSF (9.13 mg/L) had elevated inflammatory 
markers (leukocytosis, elevated protein) in the CSF. Moreover, this same subject had the 
highest serum creatinine (1 mg/dL) at the time of CSF collection which could have 
contributed to higher vancomycin and CSF exposure due to reduced renal elimination.
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Vancomycin displays time dependent activity and area under the concentration-time curve 
(AUC):MIC is the parameter found to best correlate with antimicrobial efficacy.12 In adults 
with S. aureus pneumonia or bacteremia, serum AUC:MIC>400 has been associated with 
clinical success, and has therefore become the vancomycin PK/PD target.12,13 However, this 
serum PK/PD target has not been evaluated in patients with meningitis and its extrapolation 
may not be valid due to variable vancomycin penetration in CSF. Adult studies have led to 
recommendations of trough concentrations of at least 15 mg/L for complicated infections, if 
vancomycin MIC is ≤1 µg/mL.14 In our study cohort, serum trough concentration was < 15 
mg/L in all children but 1. None of the 3 children with proven Staphylococcus spp infection 
met that target, but all cleared the infection.
The optimal method to assess vancomycin penetration into CSF is to compare AUC from 
both the CSF and serum compartments.4,15 Calculating AUC in the CSF is challenging 
because it requires multiple measurements of vancomycin over the dosing interval in the 
CSF. Because we only collected 1–3 CSF PK samples per subject, we were limited to 
calculating CSF:serum ratios at single time points. In the present study, distribution of 
vancomycin in CSF was markedly different from serum; elimination from the CSF 
compartment appeared to be slower than in serum allowing CCSF to be more stable than 
Cserum over the dosing interval (Figure 1). This difference in PK profiles partly explains why 
CSF:serum ratios (0–0.66) were variable between subjects in our cohort as well as in 
previous reports in children (0.14 to 0.68).5,7 However, a previous comparison of 
vancomycin AUC in CSF versus serum in 6 children on vancomycin therapy resulted in an 
AUC CSF:serum ratio range (0.01–0.18) comparable to the ratios observed in our study.4
Due to our inability to estimate CSF AUC:MIC as a PK/PD endpoint, we compared CCSF to 
the MIC for the 3 children with staphylococcal meningitis; only 2 of those achieved a CCSF 
above the observed MIC. Despite these findings, all three children subsequently cleared the 
infection. Among those 3 cases of documented staphylococcal infection, we found no 
correlation between CCSF and time to clear the infection. Subject #5 had the highest 
vancomycin CCSF (4.79 mg/L and 9.13 mg/L), but sterilization of CSF was slightly delayed 
compared with the 2 other children with Staphylococcus sp in their CSF (5 vs 3 days).
Results from this study highlight the need to better characterize CSF vancomycin exposure. 
Due to different PK profiles between serum and CSF, vancomycin AUCs need to be 
described in both matrices and correlated to outcomes in children with S. aureus meningitis. 
This will allow the determination of an AUC:MIC target in the CSF compartment and 
establish a valid surrogate serum PD endpoint to guide vancomycin dosing. Children with 
shunt are a population with easier access to CSF, would benefit from this knowledge and 
should be considered as a target population in future studies.
In summary, vancomycin concentrations in CSF in our cohort of children were low but 
persistently detectable across the dosing interval. Penetration ratios are variable probably 
because of a slower clearance of vancomycin in CSF compared with serum. The CSF 
concentration range described in this small cohort was associated with successful therapy. 
Future evaluations should include prospective collection of sufficient number of serum and 
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CSF concentrations to allow estimation of AUC ratios, as well as documentation of clinical 
outcomes to better identify serum PD endpoints for shunt infection.
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Figure 1. Vancomycin concentrations over time
CSF, cerebrospinal fluid
Two cerebrospinal fluid concentrations at 5 and 10 h are not paired with a predicted serum 
concentration. These concentrations are from the child who was excluded from the 
pharmacokinetic analysis due to insufficient serum sampling.
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